FDA greenlights Pfizer booster shot for certain groups; CDC advisory panel votes to recommend boosters

Sep 23, 2021 - 02:57 PM
FDA Gives Full Approval to Pfizer-BioNTech COVID-19 Vaccine. COVID-19 vaccine bottles, syringes, and COVID-19 cells.

The Food and Drug Administration late last night amended Pfizer’s emergency use authorization for its COVID-19 vaccine to allow for an additional, booster dose for certain individuals. FDA will authorize a booster shot to be administered six months following a completed two-dose regiment for the following:

  • individuals 65 years of age and older; 
  • individuals in the 18-64 age range who are at high risk of severe COVID-19; and
  • individuals in the 18-64 age range whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19, including severe disease.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today advanced the possibility of booster shots, voting unanimously to recommend boosters for the 65-and-older age group and people in long-term care facilities. ACIP also fully recommended giving a single booster dose to people between the ages of 50 and 64 with certain high risk conditions.

The ACIP meeting was continuing at the time of AHA Today’s publication, with the committee discussing occupational exposure issues that may warrant a booster. AHA tomorrow will update members on this issue.

Related News Articles

Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
FDA: Paxlovid no longer labeled for emergency use after March 8
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
FDA advisor declares ineffectiveness of widely used over-the-counter decongestant active ingredient
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
Senate committee advances bill to reauthorize preparedness programs
The Senate Health, Education, Labor and Pensions Committee today 17-3 to pass as amended the Pandemic and All-Hazards Preparedness and Response Act (S. 2333),…
Headline
FDA advisory panel recommends monovalent XBB COVID-19 vaccine for fall 
The Food and Drug Administration’s vaccine advisory committee June 15 voted unanimously to recommend updating the current COVID-19 vaccine composition for…
Headline
CDC data confirm third COVID-19 vaccine dose safe in young children
The first data on the safety of a third mRNA COVID-19 vaccine dose among young children show that a third dose is safe for children ages 6 months to 5 years…